Moreover, cBioPortal analyses of the TCGA database 28 showed a significant co-occurrence (p=0.002, Table S2) of genomic alterations of MLKL (mainly deep deletion and mutation) and BCL2L1 (BCL-x) (mainly amplification) in pan-cancer cohorts (32 studies, 10967 patients) (Fig. S4). Here, BCL2L1 is linked to cancer.